“The Starpax project is fully aligned with the overall strategy of CIUSSS du Center-Ouest-de-l’Île-de-Montreal, which places increasing emphasis on the use of new technologies and active development to meet patient needs,” he said. Lawrence Rosenberg, CEO of CIUSSS. “With the support of the government and our partners, we want to use all our world-renowned skills to reduce the burden of cancer and its treatment.”
Starpax Biopharma Inc. Has created an unprecedented 3D precision guide therapy for magnetodrons in tumors. Magnetodrons are unique bacteria made by Starpax, sensitive to the magnetic field on which drugs attach to their surfaces. Magnetodrons deliver tumor-filled drugs without circulating in the bloodstream, filling the hypoxic regions where cancer cells are difficult to reach through other treatments. Magnetodrons are injected directly into the tumor and operated by a polartrack device, where the patient is installed. Polartrack prevents magnetodrons from exiting the tumor and guides them in 3D for its special magnetic field.
“We are pleased to unveil the world’s first discovery of magnetodron precision guided therapy with Starpax PolarTrack,” he said. Michael GareuPresident and Founder Starpax Biopharma. “This unprecedented multidisciplinary technology, whose clinical results show a 100% discount ratio without any observed side effects, has brought 31 innovations, advancing microbiology, biochemistry, electromagnetics and artificial intelligence, including pharmacology, artificial intelligence.”
“We are committed to bringing this innovation here for our patients, but ultimately for patients around the world,” notes Dr. Gerald Batist, Oncologist and director of the Segal Cancer Center at JGH. “This approach offers a lot of potential and can help us better treat a variety of cancers. Innovation requires building bridges that we must overcome, as well as sharing knowledge, resources and vision to create new hope and better outcomes.” .
This new method has the potential to reduce the toxicity of treatment compared to current systemic use, thus saving long-term costs in the healthcare system.
The Ministry of Economics and Innovation has approved up to 7 million in funding for the hall. Polartrack. This funding makes it possible to cover 80% of room and equipment renovation and fitting costs. The JGH Foundation has funded 20% of this project.
“If we want to have an efficient and effective healthcare system, we must provide our experts with state-of-the-art equipment,” he said. Peter Fitzgerald, Minister of Economy and Innovation and Minister responsible for regional economic development. “This new room at the Jewish General Hospital will be able to create a direct spinoff on the dynamics of Quebec research, as well as innovate thanks to Avant-Gard treatment. This is exactly the kind of project that makes our life science industry shine here and around the world. A
The first clinical study planned on humans will focus on six types of cancer: recurrence of breast cancer, including cancer of the pancreas, prostate, head and neck, rectum, valve and skin metastases.
“The Polytechnic is proud of the scientific advances that have led to the development of this highly promising new pathway for the treatment of cancer,” he said. Giles Savard, Interim Director General of Polytechnic Montreal. “This is a great example of university research where multiple collaborations, including Starpax and Jewish General Hospital, are paving the way for applications that have a direct positive impact on society.”
The first clinical trials in humans will begin in late 2022 or early 2023.
Source Starpax Biopharma
For more information: For more details and to request an interview: For CIUSSS: [email protected]; For Starpax: [email protected]; For Minister Fitzgerald: [email protected]